Pharmacology All India exam 90edd1c7

Lutetium dotatate was approved by FDA in 2018 for

Neuroendocrine tumours

Crohn's disease

Peptic ulcer

High-Yield Explanation

Lutetium (Lu 177) dotatate a radiolabeled somatostatin analogue, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumours in adults.

← Previous Question Next Question →

Related Pharmacology MCQs

Which of the following is glucocoicoid synthesis inhibitor?

General

At a high altitude of 3000 m, a person complains of breathlessness. All of the following can...

General

All of the following drugs act on cell membrane except:

General

A non-competitive inhibitor of an enzyme?

General

Which of the following is a phase I metabolic reaction?

General

Explore All Pharmacology Questions →

Lutetium dotatate was approved by FDA in 2018 for

Related Pharmacology MCQs

Practice 2,00,000+ NEET PG Questions Free